<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01556737</url>
  </required_header>
  <id_info>
    <org_study_id>NL37475.081.11</org_study_id>
    <secondary_id>ISO II study</secondary_id>
    <nct_id>NCT01556737</nct_id>
  </id_info>
  <brief_title>Effect of Two Different Isoflavone Supplement Preparations on Gene-expression in Postmenopausal Women</brief_title>
  <acronym>ISOII</acronym>
  <official_title>Effect of Two Different Isoflavone Supplement Preparations on Gene-expression in Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wageningen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wageningen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alleged benefits experienced after the consumption of soy in Asian countries have been
      attributed to the isoflavone content of soy products. Amongst other benefits, isoflavones are
      believed to relieve menopausal symptoms and are therefore often consumed in supplement form
      in Western countries. These supplements contain relatively high amounts of isoflavones and
      are on the market in different compositions. The question is whether supplements with
      different compositions exert similar effects or whether the effects differ substantially.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intervention study with two substudies; each substudy is a double blind placebo controlled
      crossover intervention study. The first substudy has two groups: 'high daidzein' supplement
      versus placebo (n=18) and vice versa (n=18); the second substudy also has two groups 'high
      genistein' versus placebo (n=18) and vice versa (n=18).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gene-expression in PBMCs</measure>
    <time_frame>after 8 weeks exposure to supplement vs after 8 weeks exposure to placebo</time_frame>
    <description>after placebo vs after treatment measured by microarrays</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Isoflavone levels in plasma</measure>
    <time_frame>before and after 8 weeks exposure to supplement vs before and after 8 weeks exposure to placebo</time_frame>
    <description>after placebo vs after treatment measured by HPLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene - expression in adipose tissue</measure>
    <time_frame>after 8 weeks exposure to supplement vs after 8 weeks exposure to placebo</time_frame>
    <description>after placebo vs after treatment measured by QPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Isoflavone levels in adipose tissue</measure>
    <time_frame>after 8 weeks exposure to supplement vs after 8 weeks exposure to placebo</time_frame>
    <description>levels after placebo vs levels after treatment measured by HPLC</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Postmenopause</condition>
  <arm_group>
    <arm_group_label>Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High daidzein supplement</intervention_name>
    <description>8 weeks exposure to the supplement, daily 100 mg of isoflavones</description>
    <arm_group_label>Supplement</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Phyto soya forte - Arkpharma</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High genistein supplement</intervention_name>
    <description>8 weeks exposure to the supplement, daily 100 mg of isoflavones</description>
    <arm_group_label>Supplement</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Mega Soja - Springfield</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  50-70 years

          -  menstrual cycle absent for more than 1 year

        Exclusion Criteria:

          -  current use of contraceptives containing hormones

          -  current use of hormone replacement therapy

          -  regular soy product use (more than once a week)

          -  regular isoflavone supplement use (more than once a week)

          -  current use of medication containing sexhormones or sexhormone-triggering compounds

          -  current use of anti-inflammatory medicines

          -  use of antibiotics in the past 3 months

          -  severe heart disease

          -  diabetes

          -  thyroid disorders --&gt; use of medicines for thyroid disorders

          -  removed thyroid gland

          -  complete ovarectomy

          -  prior diagnosis of cancer

          -  alcohol and drug abuse

          -  current smoker

          -  BMI &gt;35 kg/m2

          -  allergy to soy (products)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pieter van 't Veer, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wageningen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wageningen University</name>
      <address>
        <city>Wageningen</city>
        <state>Gelderland</state>
        <zip>6700 EV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2012</study_first_submitted>
  <study_first_submitted_qc>March 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2012</study_first_posted>
  <last_update_submitted>October 30, 2012</last_update_submitted>
  <last_update_submitted_qc>October 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wageningen University</investigator_affiliation>
    <investigator_full_name>Lisette de Groot</investigator_full_name>
    <investigator_title>(Vera van der Velpen)</investigator_title>
  </responsible_party>
  <keyword>isoflavone</keyword>
  <keyword>supplement</keyword>
  <keyword>daidzein</keyword>
  <keyword>genistein</keyword>
  <keyword>gene expression</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genistein</mesh_term>
    <mesh_term>Daidzein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

